Table 2 Cost effectiveness results for the base case and scenario analyses
Analysis | Treatment arm | Total costs (€ 2017) | Total QALYs | Incremental Cost | Incremental QALYs | ICER |
|---|---|---|---|---|---|---|
Base case | EuroFIT | €146,629,613 | 40,531 | €654,611 (−73,893,166; 81,741,624) | 126 (−1999; 2527) | 5206 |
No intervention | €145,975,002 | 40,405 | ||||
Healthcare perspective | EuroFIT | €72,489,139 | 40,531 | €496,731 (−37,026,528; 35,107,767) | 126 (− 2026; 2537) | 3951 |
No intervention | €71,992,408 | 40,405 | ||||
Utility values from the literature | EuroFIT | €146,629,613 | 39,767 | €654,611 (−73,893,166; 81,741,624) | 564 (−68; 1106) | 1161 |
No intervention | €145,975,002 | 39,203 | ||||
EuroFIT effectiveness lasts only 1 year | EuroFIT | €147,631,100 | 40,427 | €1,759,289 (−19,869,112; 25,189,547) | 52 (− 555; 725) | 33,997 |
No intervention | €145,871,811 | 40,375 | ||||
Time horizon 10 years | EuroFIT | €303,622,814 | 71,010 | -€2,595,287 (−128,814,119; 137,269,728) | 373 (− 3254; 4534) | Dominant |
No intervention | €306,218,101 | 70,636 |